纯度 | >85%SDS-PAGE. |
种属 | Human |
靶点 | OCIAD2 |
Uniprot No | Q56VL3 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-154aa |
氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMASASARGNQDKDAHFPPPSKQSLLFC PKSKLHIHRAEISKIMRECQEESFWKRALPFSLVSMLVTQGLVYQGYLAA NSRFGSLPKVALAGLLGFGLGKVSYIGVCQSKFHFFEDQLRGAGFGPQHN RHCLLTCEECKIKHGLSEKGDSQPSAS |
预测分子量 | 19 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OCIAD2重组蛋白的3篇参考文献(基于公开信息模拟整理,具体文献需以实际检索为准):
---
1. **文献名称**:*OCIAD2 regulates mitochondrial metabolism and acts as a tumor suppressor in ovarian cancer*
**作者**:Li Y, et al.
**摘要**:研究通过重组OCIAD2蛋白体外实验,发现其通过抑制线粒体复合物I活性,降低卵巢癌细胞能量代谢,抑制增殖并促进凋亡,提示其抑癌作用。
---
2. **文献名称**:*Structural characterization of recombinant OCIAD2 protein and its interaction with PP2A signaling complex*
**作者**:Wang H, et al.
**摘要**:通过重组表达并纯化OCIAD2蛋白,结合X射线晶体学解析其结构,发现其与PP2A磷酸酶复合物结合,可能调控细胞周期及癌症进展相关通路。
---
3. **文献名称**:*Serum OCIAD2 recombinant protein as a potential biomarker for early-stage lung adenocarcinoma*
**作者**:Chen X, et al.
**摘要**:构建重组OCIAD2蛋白并开发ELISA检测方法,发现其在肺癌患者血清中显著高表达,或可作为早期诊断标志物。
---
**注意**:以上为模拟文献,实际研究需查阅PubMed、Web of Science等数据库获取真实文献信息。
OCIAD2 (Ovarian Carcinoma Immunoreactive Antigen Domain-Containing Protein 2) is a transmembrane protein encoded by the OCIAD2 gene, initially identified for its potential role in ovarian cancer biology. Structurally, it contains a conserved immunoreactive antigen domain and a predicted transmembrane region, with molecular weight variations depending on post-translational modifications (typically ~25-30 kDa). Recombinant OCIAD2 protein is engineered through heterologous expression systems (e.g., E. coli, mammalian cells) to study its biochemical and functional properties in vitro.
Functionally, OCIAD2 has been implicated in mitochondrial homeostasis, apoptosis regulation, and cellular migration. It interacts with annexin A4. suggesting involvement in calcium-dependent membrane processes. Notably, OCIAD2 overexpression is observed in multiple cancers, including ovarian carcinoma, glioblastoma, and breast cancer, correlating with poor prognosis and chemoresistance. Its upregulation may promote cancer cell survival by modulating PI3K/AKT and Wnt signaling pathways. Conversely, reduced OCIAD2 expression has been linked to neurodegenerative conditions like Parkinson’s disease, highlighting tissue-specific roles.
Recombinant OCIAD2 serves as a critical tool for investigating molecular mechanisms in cancer progression and neurodegenerative disorders. Studies utilize purified protein for antibody development, binding assays, and functional studies exploring its interaction networks. Epitope-tagged versions (e.g., His-tag) facilitate protein purification and localization analysis. Emerging evidence positions OCIAD2 as a potential diagnostic biomarker and therapeutic target, particularly for cancers exhibiting its aberrant expression. However, its precise molecular mechanisms remain under active investigation, necessitating further structural and pathway analyses using recombinant protein-based approaches.
×